Skip to main content
TipRanks
Go Ultimate75% OFF

Faes Farma (FAE) AI Stock Analysis

23 Followers
ES:FAE

Faes Farma

(BME:FAE)

Select Model
Rating:70Outperform
Price Target:EUR 5.50â–²(8.27% Upside)
Action:upgraded
Date:11/06/26

The overall score reflects a balanced profile. The company's consistent revenue growth and attractive valuation (low P/E, decent yield) are key strengths. These are tempered by significant margin pressure and weaker cash flow, likely tied to a recent acquisition. Technical trends are supportive, with the stock in a steady uptrend.

Positive Factors
Historical ProfitabilityStrong profitability over several years indicates established earnings power and an operating model that has historically converted demand into attractive margins. This provides a durable base for investment in products, manufacturing and commercial capabilities despite the latest slowdown.
Negative Factors
Recent Revenue and Margin DeclineThe 2025 deterioration signals a meaningful loss of operating momentum after several stronger years. Lower revenue and compressed margins can weaken reinvestment capacity and make future earnings more dependent on successful execution and recovery in demand.

Faes Farma (FAE) vs. iShares MSCI Spain ETF (EWP)

-5%0%5%10%15%20%25%30%35%ES:FAE+12.76%EWP+21.91%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 1.58B
Dividend Yield
2.52%
Average Volume (3M)
170.08K
Price to Earnings (P/E)
11.7
Beta (1Y)
0.44
Revenue Growth
31.88%
EPS Growth
-20.09%
Country
Spain
Employees
2,677
Sector
General
Sector Strength
55
Industry
Drug Manufacturers - Specialty & Generic

Faes Farma Business Overview & Revenue Model

Company Description

Faes Farma, S.A. is a pharmaceutical enterprise dedicated to the research, development, manufacture, and distribution of both finished medicinal products and crucial raw materials. Its extensive operations span Spain and a multitude of international...

How the Company Makes Money

Faes Farma makes money primarily by selling healthcare products, with revenue generated from: (1) Prescription pharmaceuticals: income from the commercialization of branded medicines and other prescription products sold through pharmaceutical distrib...

Faes Farma Financial Statement Overview

Summary

Faes Farma shows consistent revenue growth (~10% CAGR) and a solid balance sheet with moderate leverage (D/E 0.55). However, recent margin compression (gross margin fell to 37%) and weakened cash flow reduce the score from higher levels.

Income Statement

70Positive

Balance Sheet

75Positive

Cash Flow

65Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.04B610.46M493.65M451.17M438.75M398.56M
Gross Profit312.17M228.46M326.54M297.12M282.01M252.40M
EBITDA167.65M101.80M128.33M122.93M121.35M110.84M
Net Income136.19M79.63M111.36M91.90M89.50M82.39M
Balance Sheet
Total Assets1.44B1.34B853.08M776.03M725.67M641.76M
Cash, Cash Equivalents and Short-Term Investments136.78M130.09M72.14M47.75M84.10M73.41M
Total Debt396.85M409.91M7.79M23.90M32.69M16.44M
Total Liabilities664.48M594.19M126.46M112.68M123.39M103.70M
Stockholders Equity774.45M744.80M725.87M662.36M601.08M536.53M
Cash Flow
Free Cash Flow61.63M62.38M75.95M-1.22M25.84M20.23M
Operating Cash Flow79.45M78.49M115.47M100.97M106.79M79.64M
Investing Cash Flow-241.15M-299.02M-34.18M-97.36M-92.17M-83.48M
Financing Cash Flow182.02M273.62M-51.71M-35.38M-18.46M-17.12M

Faes Farma Technical Analysis

Technical Analysis SentimentPositive
Last Price5.08

Price Trends

50DMA4.72Positive
100DMA4.62Positive
200DMA4.66Positive

Market Momentum

MACD0.08Negative
RSI67.85Neutral
STOCH90.46Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:FAE, the sentiment is Positive. The current price of 5.08 is above the 20-day moving average (MA) of 4.83, above the 50-day MA of 4.72, and above the 200-day MA of 4.66, indicating a bullish trend. The MACD of 0.08 indicates Negative momentum. The RSI at 67.85 is Neutral, neither overbought nor oversold. The STOCH value of 90.46 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ES:FAE.

Faes Farma Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

ES:FAE against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
ES:NTHES:NTH81OutperformEUR 130.69M15.0152.07%11.47%-6.06%-15.89%
ES:GRFES:GRF75OutperformEUR 6.93B16.128.83%0.71%1.03%30.59%
ES:LOGES:LOG72OutperformEUR 4.99B17.7543.48%5.58%2.23%0.36%
ES:ALMES:ALM70OutperformEUR 2.32B31.694.81%1.73%9.67%174.00%
ES:FAEES:FAE70OutperformEUR 1.58B11.6818.19%2.52%31.88%-20.09%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
ES:RJFES:RJF47NeutralEUR 214.07M30.703.14%0.75%-0.42%4.56%

* General Sector Average

Performance Comparison

0%20%ES:FAEES:ALMES:GRFES:RJFES:LOGES:NTHDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
ES:FAE and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
ES:FAEFaes Farma5.080.5812.89%
ES:ALMAlmirall SA10.64-1.50-12.35%
ES:GRFGrifols (0RDU)11.611.3713.35%
ES:RJFLABORATORIO REIG JOFRE2.60-0.05-1.92%
ES:LOGCompania de Distribucion Integral Logista Holdings37.8010.0436.18%
ES:NTHNaturhouse Health2.180.3217.39%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 04, 2026